At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 350 target
Drug / intervention
ZG006 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II Study of the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Combination With ZG005 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma(NEC)
In Brief
A Phase 2 clinical trial evaluating ZG006 and ZG005 for Small Cell Lung Cancer and Neuroendocrine Carcinoma. Currently recruiting, targeting 350 participants across 1 site.
Detailed Summary
This study is a randomized, multicenter, Phase Ib/II clinical trial, aimed at evaluating the efficacy and safety of the combination of ZG006 and ZG005 in patients with advanced small cell lung cancer and neuroendocrine carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Lung Cancer, Neuroendocrine Carcinoma
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
20262027
First PostedJun 2025
Enrollment StartSep 2025
TodayJul 2026
Primary CompletionSep 2027
First PostedJun 26, 2025
Enrollment StartSep 23, 2025
Primary CompletionSep 1, 2027
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 1.0 years agoPrimary completion in 1.2 years
Interventions
ZG006drug
ZG006 will be administered as an intravenous (IV) infusion.
ZG005drug
ZG005 will be administered as an intravenous (IV) infusion.